INTRODUCTION
============

Morphine is the first-line choice for the management of chronic, moderate-to-severe pain in both cancer and non-cancer patients ([@b15-molce-39-9-645]; [@b43-molce-39-9-645]; [@b74-molce-39-9-645]; [@b105-molce-39-9-645]; [@b106-molce-39-9-645]). Unfortunately, long-term treatment with morphine ultimately results in tolerance to morphine's analgesic effect ([@b76-molce-39-9-645]; [@b117-molce-39-9-645]), limiting its efficacy in clinical practice. A higher dose of morphine is often used to overcome tolerance, but this strategy exposes patients to a higher risk of developing severe side effects, such as morphine rewarding and withdrawal symptoms ([@b59-molce-39-9-645]; [@b63-molce-39-9-645]). Thus, there is a need to understand the molecular and functional mechanisms of morphine addiction to develop less addictive therapeutic substitutes for morphine. Recently, a number of studies have provided evidence for the complexity of anatomical and functional interactions between neurons in brain reward circuits prompted by morphine's rewarding action ([Fig. 1](#f1-molce-39-9-645){ref-type="fig"}; [Table 1](#t1-molce-39-9-645){ref-type="table"}). Here, we review the neuronal interactions in brain reward circuits under morphine reward.

VENTRAL TEGMENTAL AREA (VTA)-NUCLEUS ACCUMBENS (NAC) CIRCUIT: DOPAMINERGIC (DA)/GAMMA-AMINOBUTYRIC ACID (GABA)ERGIC TRANSMISSION
================================================================================================================================

The mu-opioid receptor (MOR) is key to morphine's action, and there are several lines of evidence on the strong relationship between MOR activation in the ventral tegmental area (VTA) and reinforcing the effects of morphine. The VTA contains many MORs, and intra-VTA injection of a MOR antagonist significantly reduced morphine-induced conditioned place preference (CPP) ([@b73-molce-39-9-645]; [@b86-molce-39-9-645]). Additionally, a behavioral study using delta-opioid-receptor (DOR) knockout mice and a DOR antagonist showed that DOR prevented the rewarding effects of morphine, suggesting that the action of DOR on morphine affects the nucleus accumbens (NAc) gamma-aminobutyric acid (GABA)ergic and VTA dopaminergic (DA) neurons ([@b14-molce-39-9-645]). However, there is a report that the systemic injection of the kappa-opioid receptor (KOR) does not alter the VTA DA release induced by DAMGO ([@b27-molce-39-9-645]). Furthermore, several studies have shown the changes in dopamine receptors during morphine reward and withdrawal in VTA-NAc circuits ([@b12-molce-39-9-645]; [@b80-molce-39-9-645]).

For example, [@b12-molce-39-9-645] presented molecular evidence that a D1 receptor agonist significantly reduced MOR-antagonist-induced somatic withdrawal symptoms and increased GluR1 phosphorylation in the NAc of morphine-dependent rats. Additionally, D1 dopamine and an N-methyl-d-aspartic acid (NMDA) glutamate receptor antagonist significantly reduced Fos protein, which systemic morphine up-regulated, in the NAc and substantia nigra (SN) ([@b8-molce-39-9-645]; [@b80-molce-39-9-645]).

The VTA sends a dense pack of dopaminergic projections to the GABAergic medium spiny neurons (MSNs) in both the shell and core regions of the nucleus accumbens ([Fig. 1](#f1-molce-39-9-645){ref-type="fig"}; [Table 1](#t1-molce-39-9-645){ref-type="table"}). Between the two sub-regions, dopaminergic transmission to the NAc shell is stimulated preferentially by morphine reward ([@b61-molce-39-9-645]; [@b90-molce-39-9-645]). Specifically, it has been found that within VTA-NAc pathways, tyrosine hydroxylase (TH), a well-known enzyme in the biosynthesis of dopamine ([@b20-molce-39-9-645]), is up-regulated level of TH expression in response to chronic morphine treatment indicates that up-regulated level of dopamine in the VTA-NAc circuits may play an important role in morphine and other opioid rewards ([@b5-molce-39-9-645]). Consistent with this, a study by [@b65-molce-39-9-645] confirmed dynamic changes in TH expression in VTA-NAc projection neurons by morphine-induced CPP in rats. Furthermore, acute treatment with morphine to rats followed by prolonged abstinence induces burst firing of VTA dopaminergic neurons, which are thought to play a role in encoding reward value ([@b25-molce-39-9-645]; [@b35-molce-39-9-645]; [@b48-molce-39-9-645]; [@b107-molce-39-9-645]). A potential explanation for the increased burst firing rate of VTA dopaminergic neurons is reduced neuronal size. Chronic morphine treatment can reduce the size of VTA dopaminergic neurons, and smaller neurons are known to have lower membrane resistance, which could increase the overall neural firing rate in mice ([@b16-molce-39-9-645]; [@b102-molce-39-9-645]). Indeed, *in vivo* recording of mice brain has shown that chronic morphine treatment increased the basal firing rate and the burst firing rate in VTA dopaminergic neurons ([@b54-molce-39-9-645]).

Dopaminergic transmission in VTA-NAc circuits can be modulated by effects of morphine treatment via cannabinoid and cholinergic systems ([@b17-molce-39-9-645]; [@b50-molce-39-9-645]; [@b53-molce-39-9-645]; [@b75-molce-39-9-645]; [@b93-molce-39-9-645]; [@b98-molce-39-9-645]). For example, [@b115-molce-39-9-645] suggested that cannabinoids can activate VTA-NAc dopaminergic transmission by a common MOR-dependent mechanism shared with opioids, suggesting the possibility of crosstalk between cannabinoid and morphine signaling pathways. There is ultrastructural evidence that cannabinoid receptor type 1 (CB1)-labeled terminals interacted with 19% of the NAc shell and 13% of the NAc core containing MOR, and MOR-labeled terminals contacted 20% of the NAc shell and 10% of the NAc core containing CB1 receptors, suggesting the role of CB1 receptors in the rat NAc ([@b88-molce-39-9-645]). Indeed, intra-NAc injection of a CB1 receptor agonist can potentiate the rewarding effect of low-dose morphine and induce CPP, while a CB1 receptor antagonist inhibited morphine-induced CPP in rats ([@b50-molce-39-9-645]). Additionally, cholinergic inputs to the VTA can control morphine reward as well as morphine related-learning and locomotion by activating VTA dopaminergic neurons ([@b19-molce-39-9-645]; [@b97-molce-39-9-645]; [@b98-molce-39-9-645]; [@b110-molce-39-9-645]). Morphine treatment induces a long-lasting increase in the cholinergic modulation of GABA synapses in the NAc, suggesting a modulatory role for cholinergic systems on the VTA-NAc dopaminergic system in adult rats ([@b26-molce-39-9-645]).

Along with dopaminergic efferents, the VTA receives GABAergic inputs from the rostromedial tegmental nucleus (RMTg) and the NAc ([Fig. 1](#f1-molce-39-9-645){ref-type="fig"}; [Table 1](#t1-molce-39-9-645){ref-type="table"}). They are believed to modulate the activity of VTA dopaminergic neurons ([@b54-molce-39-9-645]; [@b113-molce-39-9-645]; [@b116-molce-39-9-645]; [@b118-molce-39-9-645]). For example, during acute morphine treatment and withdrawal, VTA dopaminergic neurons are activated by disinhibition of GABAergic projections from the RMTg in rats ([@b22-molce-39-9-645]; [@b51-molce-39-9-645]; [@b62-molce-39-9-645]). Additionally, optogenetic stimulation of GABAergic inputs to VTA of mice brain can strongly inhibit the activity of VTA dopaminergic neurons and induce conditioned place aversion ([@b113-molce-39-9-645]). However, it remains to be determined how GABAergic inputs on VTA dopaminergic neurons modulate morphine-dependent states.

Collectively, activation of dopaminergic neurons can potently modulate morphine reward. However, non-dopaminergic circuits also contribute to morphine reward ([@b79-molce-39-9-645]; [@b83-molce-39-9-645]) but, currently, our knowledge of the non-dopaminergic circuits is limited. Understanding the contribution of VTA dopaminergic and non-dopaminergic circuits to morphine reward is important in future studies.

VTA-AMYGDALA/BED NUCLEUS OF THE STRIA TERMINALIS (BNST) CIRCUIT: DOPAMINERGIC/GLUTAMATERGIC/GABAERGIC TRANSMISSION
==================================================================================================================

The amygdala is located in the medial temporal lobe and has 13 sub-regions, including the basolateral amygdala (BLA) and the central amygdala (CeA) ([@b3-molce-39-9-645]; [@b109-molce-39-9-645]). Several human studies have provided evidence for the role of the amygdala in drug-seeking behavior ([@b13-molce-39-9-645]; [@b58-molce-39-9-645]).

The BLA is thought to be a key region for reconsolidation of drug-related memory and reinstatement of drug-seeking behaviors ([@b38-molce-39-9-645]; [@b51-molce-39-9-645]). The VTA sends dopaminergic projections to the BLA and induces associative neuronal plasticity in the amygdala ([@b7-molce-39-9-645]; [@b37-molce-39-9-645]) ([Fig. 1](#f1-molce-39-9-645){ref-type="fig"}; [Table 1](#t1-molce-39-9-645){ref-type="table"}). BLA-projecting VTA neurons are regulated by opioid agonists independently from NAc-projecting VTA neurons, indicating that VTA dopaminergic neurons are heterogeneous and the opioid-induced behavioral effects may vary by specific changes in distinct subpopulations of dopaminergic neurons within the VTA ([@b37-molce-39-9-645]). Similarly, [@b67-molce-39-9-645] reported that blockade of dopa mine D1 and D2 receptors in the BLA of Sprague Dawley (SD) rats can modulate intra-VTA morphine-induced CPP in both morphine-naïve and -dependent states.

The CeA sends out GABAergic projections that primarily control GABAergic drive in the bed nucleus of the stria terminalis (BNST), which receives dopaminergic inputs from the VTA ([@b28-molce-39-9-645]; [@b65-molce-39-9-645]; [@b99-molce-39-9-645]; [@b124-molce-39-9-645]) ([Fig. 1](#f1-molce-39-9-645){ref-type="fig"}; [Table. 1](#t1-molce-39-9-645){ref-type="table"}). Intra-CeA injection of a D1 or D2 receptor agonist can induce morphine-induced CPP in rats ([@b96-molce-39-9-645]; [@b122-molce-39-9-645]). In turn, chronic morphine treatment increases FosB expression in the CeA of rats, indicating initiation or maintaining of state of rewarding ([@b82-molce-39-9-645]; [@b85-molce-39-9-645]). [@b72-molce-39-9-645] also showed that inhibition of the CeA of rat brain reduced morphine-induced CPP and foot shock-induced CPP reinstatement with concurrent reduction of Fos expression in the BNST and the VTA, but Fos expression in the BNST was not altered by CeA modulation. [@b36-molce-39-9-645] examined that MOR activation on CeA-projecting GABAergic BLA neurons decreased GABAergic inputs to CeA via Kv1.1 and Kv1.2 signaling. Also, molecular and behavioral studies have shown the possible involvement of CeA in expression and reinstatement of morphine-induced CPP. Furthermore, [@b120-molce-39-9-645] suggested that non-dopaminergic systems, such as the noradrenergic system, also contribute to morphine rewarding in the CeA. The BNST sends glutamatergic and GABAergic projections to the VTA ([@b49-molce-39-9-645]; [@b56-molce-39-9-645]; [@b57-molce-39-9-645]; [@b118-molce-39-9-645]). An early study provided electrophysiological evidence that chronic morphine can selectively increase α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-mediated excitatory postsynaptic currents in specific VTA-projecting BNST neurons of rats ([@b29-molce-39-9-645]). To support this result, more recent studies also found that optogenetic or pharmacological activation of GABAergic projections from the BNST to the VTA can inhibit VTA dopaminergic transmission ([@b49-molce-39-9-645]; [@b118-molce-39-9-645]). Collectively, these findings indicate that amygdala subcircuits to the VTA may play important roles in modulating diverse components in morphine addiction.

VTA-MEDIAL PREFRONTAL CORTEX (MPFC)/NAC CIRCUIT: DOPAMINERGIC/GLUTAMATERGIC TRANSMISSION
========================================================================================

The VTA sends dopaminergic projections to the mPFC, while the mPFC sends glutamatergic projections to both the VTA and the NAc ([@b87-molce-39-9-645]; [@b108-molce-39-9-645]) ([Fig. 1](#f1-molce-39-9-645){ref-type="fig"}; [Table 1](#t1-molce-39-9-645){ref-type="table"}). Several studies have demonstrated that the VTA-mPFC circuit is involved in morphine reward. For example, intra-VTA infusion of a MOR agonist increased the dopamine level in the mPFC, and a decreased dopamine level in the mPFC can disrupt acquisition of mu-opioid agonist-induced CPP in rats ([@b81-molce-39-9-645]). Furthermore, pharmacological blockade of either mPFC AMPA or NMDA receptors in the mPFC of rats increases morphine-induced CPP to its sub-threshold dose and decreases dopamine release properties as changes of firing and bursting activities in VTA dopaminergic neurons ([@b23-molce-39-9-645]; [@b114-molce-39-9-645]). However, either cellular or molecular contributions of altered glutama-tergic transmission from the mPFC to VTA dopaminergic neurons in morphine addiction remains to be determined.

Another bidirectional circuit in the mPFC is the retrograde signaling of endocannabinoids from the VTA ([@b112-molce-39-9-645]). Cannabinoid transmission through CB1 receptor in mPFC is known to modulate emotional processing, memory, and balance of morphine-related reward and aversion in rats ([@b1-molce-39-9-645]; [@b78-molce-39-9-645]). According to [@b1-molce-39-9-645], activation of CB1 transmission induces aversion to morphine, whereas inhibition of CB1 transmission produces motivation towards morphine. This bidirectional control of morphine preference could be interpreted with the mPFC-VTA circuit. Low activation of CB1 receptors in the mPFC is known to increase the spontaneous firing of VTA dopaminergic neurons, whereas high activation inhibits spontaneous dopaminergic neuron activity ([@b1-molce-39-9-645]). The major modulatory signaling in the mPFC-VTA circuit for morphine reward may be inhibitory, because CB1 receptors in the mPFC can control VTA dopaminergic transmission through GABAergic signaling ([@b18-molce-39-9-645]; [@b21-molce-39-9-645]). Together, these studies suggest that CB1 transmission from the mPFC plays a prominent role in emotional processing for morphine through the modulation of VTA dopaminergic neurons.

VTA-HIPPOCAMPUS CIRCUIT: DOPAMINERGIC/GLUTAMATERGIC TRANSMISSION
================================================================

According to [@b69-molce-39-9-645], the hippocampus-VTA circuit consists of bidirectional pathways. The first pathway involves dopaminergic projections from the VTA to the hippocampus ([Fig. 1](#f1-molce-39-9-645){ref-type="fig"}; [Table 1](#t1-molce-39-9-645){ref-type="table"}). Dopamine transmission can induce long-term potentiation (LTP) in the hippocampus when presented with novel stimuli in rodents ([@b40-molce-39-9-645]; [@b69-molce-39-9-645]; [@b104-molce-39-9-645]). Accordingly, the role of the VTA-hippocampus circuit in rewards could be involved in, and may be restricted to, the acquisition of novel rewarding stimuli in the fMRI study using human brain ([@b9-molce-39-9-645]). Recent studies in morphine reward also showed a role for the VTA-hippocampus in the acquisition of morphine-induced CPP. For example, administering an antagonist of D1 or D2 receptors in the hippocampal CA1 can inhibit the acquisition of intra-VTA morphine-induced CPP in rats ([@b31-molce-39-9-645]; [@b45-molce-39-9-645]). The second pathway is from the hippocampus to the VTA, which is activated when the hippocampus detects a previously learned rewarding cue ([@b69-molce-39-9-645]) and plays a role in spatial reinforcement learning ([@b52-molce-39-9-645]). This circuit is also intermingled with other brain regions. Specifically, hippocampal CA3 glutamatergic neurons can activate GABAergic neurons of the caudodorsal lateral septum and the NAc, which, in turn, increase dopamine releases in the VTA by the disinhibition of GABAergic projections to the VTA ([@b71-molce-39-9-645]). Together, these studies suggest a relationship between morphine reward and the hippocampus-VTA circuit.

AMYGDALA-NAC/HIPPOCAMPUS/MPFC CIRCUIT: GLUTAMATERGIC TRANSMISSION
=================================================================

The BLA sends glutamatergic projections to NAc GABAergic neurons, and neurotransmission within BLA-NAc circuit is involved in reward-seeking behavior ([@b2-molce-39-9-645]; [@b33-molce-39-9-645]; [@b109-molce-39-9-645]) ([Fig. 1](#f1-molce-39-9-645){ref-type="fig"}; [Table 1](#t1-molce-39-9-645){ref-type="table"}). Specifically, BLA projections to NAc neurons are necessary for cue-evoked excitation of NAc neurons, through which the excited NAc neurons promote reward-seeking behavior ([@b2-molce-39-9-645]). Additionally, BLA efferents to the NAc shell can control opiate reward via differential regulation of D1 or D2 receptor signaling in rats ([@b65-molce-39-9-645]).

The BLA also sends glutamatergic projections to the hippocampus ([@b95-molce-39-9-645]), and the synaptic plasticity induced by BLA-hippocampus glutamatergic transmission mediates the formation of learning and memory required for opioid addiction ([@b30-molce-39-9-645]; [@b46-molce-39-9-645]; [@b70-molce-39-9-645]; [@b91-molce-39-9-645]). Also, cannabinoids are involved in hippocampal reward-related learning by modulating glutamatergic transmission in rodents ([@b89-molce-39-9-645]; [@b123-molce-39-9-645]). However, the neuronal interplay between the BLA and the hippocampus still needs to be clarified in the context of morphine reward. The mPFC receives glutamatergic inputs from the BLA, and this circuit plays a role in memory consolidation ([@b121-molce-39-9-645]). The mPFC is known to be related to the formation of associative memory between morphine and non-salient cues, and relapse in morphine addiction in rodents animal models ([@b23-molce-39-9-645]; [@b64-molce-39-9-645]; [@b119-molce-39-9-645]). Furthermore, the mPFC is believed to be important for processing salient information that drives conditioned behavioral responses ([@b92-molce-39-9-645]; [@b109-molce-39-9-645]). Consistent with this, [@b42-molce-39-9-645] revealed that protein synthesis in the BLA controls the consolidation of morphine-related memory in mPFC via calcium/calmodulin-dependent protein kinase II (CaMKII) signaling. Additionally, a morphine-related memory switch is controlled by D2 receptor-CaMKII signaling within the BLA-mPFC circuit in rats ([@b101-molce-39-9-645]). Specifically, blockade of NMDA receptors in the prelimbic subdivision of the mPFC of rats can strongly potentiate the rewarding effects of systemic and intra-VTA morphine treatment, but inactivation of the BLA blocks this behavioral potentiation ([@b6-molce-39-9-645]). Together, these data suggest that chronic morphine treatment induces excitatory synaptic drive in the BLA-NAc circuit that is strongly involved in morphine addiction, and demonstrate that the BLA-mPFC circuit plays an important role in drug-related cue learning.

LATERAL HYPOTHALAMUS (LH)-VTA CIRCUIT: OREXINERGIC TRANSMISSION
===============================================================

Hypothalamus neurons in the brain are known to exclusively produce orexin neuropeptides that bind to orexin-1 or orexin-2 receptors ([@b24-molce-39-9-645]; [@b103-molce-39-9-645]). The hypothalamus consists of small sub-regions, and each has varied and segregated functions ([@b77-molce-39-9-645]). Among the sub-regions, the lateral hypothalamus (LH) is considered to play a role in reward-related behavior ([@b10-molce-39-9-645]; [@b11-molce-39-9-645]; [@b100-molce-39-9-645]).

Fifty percent of LH neurons are orexinergic neurons ([@b41-molce-39-9-645]), while the other 50% consists of various other neuropeptidergic neurons, including glucagon-like peptide-1, oxytocin, and arginine-vasopressin neurons ([@b24-molce-39-9-645]; [@b77-molce-39-9-645]). The transmission from LH orexinergic neurons to VTA dopaminergic neurons is mediated by the orexin-1 receptors ([@b94-molce-39-9-645]). LH orexinergic neurons have a role in rewarding, withdrawal, and synaptic plasticity induced by morphine ([@b4-molce-39-9-645]; [@b41-molce-39-9-645]). For example, withdrawal after treatment with an escalating dose of morphine for 10 days caused the up-regulation of MOR and orexin mRNA in the LH, as well as the striatum ([@b126-molce-39-9-645]). In addition, [@b41-molce-39-9-645] reported that MOR on LH orexinergic neurons induced cAMP response element-binding protein (CREB) and c-Fos expression during chronic morphine exposure and withdrawal using orexin knockout mice. Furthermore, LH orexin knockout mice show reduced both rewarding and withdrawal responses ([@b41-molce-39-9-645]).

The circuitry between the LH and VTA could indirectly or directly control rewarding effects of morphine ([@b4-molce-39-9-645]; [@b47-molce-39-9-645]) ([Fig. 1](#f1-molce-39-9-645){ref-type="fig"}; [Table 1](#t1-molce-39-9-645){ref-type="table"}). Specifically, activation of LH orexinergic neurons by rat pancreatic polypeptide or intra-VTA injection of orexin can reinstate previously extinguished morphine-induced CPP in rats ([@b47-molce-39-9-645]). Furthermore, morphine exposure-mediated modulation of the orexin-1 receptors in VTA dopaminergic neurons can increase presynaptic glutamate releases and decrease GABA releases, supporting the idea that LH orexinergic projections to VTA dopaminergic neurons play a modulatory role in morphine reward ([@b4-molce-39-9-645]).

DORSAL STRIATUM (DST)
=====================

The role of the dorsal striatum (dST) in addiction is important in the development of habitual and compulsive drug use ([@b34-molce-39-9-645]; [@b55-molce-39-9-645]). Especially within the dST, the dorsomedial striatum is more closely related to acquisition and drug seeking than the dorsolateral striatum ([@b32-molce-39-9-645]). [@b84-molce-39-9-645] reported that injection of a transient receptor potential vanilloid type 1 (TRPV1) antagonist into the dST inhibited morphine-induced MOR interaction proteins, such as adenylyl cyclase 1 (AC), p38 mitogen-activated protein kinase (p38 MAPK), and nuclear factor kappa B (NF-κB), suggesting the important role of MOR in the dST.

Moreover, many studies stressed that the dST and the NAc shell play roles in morphine-seeking behavior induced by drug-associated cues ([@b8-molce-39-9-645]; [@b39-molce-39-9-645]; [@b44-molce-39-9-645]; [@b111-molce-39-9-645]). More specifically, morphine-induced MOR activation in the SN and the VTA leads to Fos expression within the dST of rats, suggesting dST function is controlled by dST projecting VTA dopaminergic neurons ([@b8-molce-39-9-645]) ([Fig. 1](#f1-molce-39-9-645){ref-type="fig"}; [Table 1](#t1-molce-39-9-645){ref-type="table"}). Additionally, chronic morphine can decrease expression of the delta-opioid receptor in the cholinergic interneurons of the dorsolateral striatum ([@b60-molce-39-9-645]). A recent study by [@b125-molce-39-9-645] reported that morphine induced two distinct episodes of immediate early gene induction in the dST, where the first was related to the dST-NAc shell circuits and the subsequent expression was related to the dST-cortex circuits in mice ([@b125-molce-39-9-645]). These studies suggest a role for the dST in morphine reward.

CONCLUSION
==========

Brain reward circuitry studies have provided an improved mechanistic understanding of morphine addiction. Specifically, clarifying the causal relationship within reward circuitry has served to further interpret morphine-specific functional and molecular changes in multiple reward-related brain regions. Various changes are reflected in the distinct connectivity and function of brain reward circuits. In this era, advances in sophisticated imaging, tracing, and genetic and optogenetic tools make it possible to analyze the complex neural networks underlying the morphine-specific brain reward circuits. With these new tools, future studies should focus on identifying the exact afferents and efferents modulated under specific symptoms of morphine reward, which may provide novel pharmacological targets for the treatment of morphine addiction.
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![Schematic diagram of brain reward circuits involved in morphine reward. The ventral tegmental area (VTA) projects dopaminergic (purple) transmission to the nucleus accumbens (NAc), medial prefrontal cortex (mPFC), hippocampus (Hipp), bed nucleus of the stria terminalis (BNST), amygdala (Amy), dorsal striatum (dST) and it modulates glutamatergic (blue) and gamma-aminobutyric acid (GABA) ergic (green) transmission. VTA dopaminergic (DA) neurons are also modulated by lateral hypothalamus (LH) orexinergic (yellow) neurons and rostromedial tegmental nucleus (RMTg) GABAergic neurons. Glutamatergic projections from the mPFC and Amy innervate the NAc to modulate NAc GABAergic transmission to the VTA, and glutamatergic transmission from the mPFC and BNST modulates VTA DA neurons.](molce-39-9-645f1){#f1-molce-39-9-645}
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Overview of the brain reward circuits in morphine reward

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Circuits                 Tools                                                                     Phenotype                                                                                                                        Projection type                        References
  ------------------------ ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------
  RMTg→VTA                 Antero/Retrograde tracer                                                  Inactivation of RMTg reduces morphine-induced increase of impulse activity of VTA DA neurons                                     GABAergic transmission                 [@b22-molce-39-9-645]

  Pharmacology                                                                                                                                                                                                                                                               

  VTA→NAc                  Optogenetic stimulation                                                   Optical stimulation of VTA DA terminal in NAc increases morphine-induced CPP                                                     Dopaminergic transmission              [@b54-molce-39-9-645]

  VTA→BLA                  Retrograde tracer *ex vivo* electrophysiology                             MOR agonist induces greater inhibition of BLA-projecting neurons than NAc projecting neurons                                     Dopaminergic transmission              [@b37-molce-39-9-645]

  Pharmacology             Intra-VTA morphine-induced CPP was controlled by BLA Dopamine receptors   Dopaminergic transmission                                                                                                        [@b67-molce-39-9-645]                  

  BNST→VTA                 Retrograde tracer                                                         Chronic morphine treatment up-regulated the excitatory transmission in a subpopulation of BNST neurons that project to the VTA   Glutamatergic/GABAergic transmission   [@b29-molce-39-9-645]

  Electrophysiology                                                                                                                                                                                                                                                          

  CeA→BNST                 Pharmacology                                                              Inhibition of CeA GABA neurons reducedmorphine-induced CPP and reinstatement with Fos expression in BNST                         GABAergic transmission                 [@b72-molce-39-9-645]

  BLA→NAc                  Pharmacology                                                              Inhibition of NAc NMDA transmission blocks potentiation of intra-BLA morphine-induced CPP                                        Glutamatergic transmission             [@b65-molce-39-9-645]

  BLA→mPFC                 Pharmacology                                                              mPFC projecting BLA neurons control morphine rewarding via CaMKII signaling/NMDA signaling                                       Glutamatergic transmission             [@b42-molce-39-9-645]

  [@b101-molce-39-9-645]                                                                                                                                                                                                                                                     

  VTA→mPFC                 Retrograde tracer                                                         Lesion of VTA DA terminal to mPFC blocks infra-VTA MOR agonist induced CPP                                                       Dopaminergic transmission              [@b81-molce-39-9-645]

  Pharmacology                                                                                                                                                                                                                                                               

  mPFC→VTA                 Pharmacology                                                              Decreased glutamate transmission via NMDAR and AMPAR enhances morphine-induced CPP                                               Glutamatergic transmission             [@b6-molce-39-9-645]

  mPFC↔VTA                 Pharmacology                                                              Inactivated CB1 receptors induce motivational valence to morphine                                                                Cannabinoidergic transmission          [@b23-molce-39-9-645]\
                                                                                                                                                                                                                                                                             [@b1-molce-39-9-645]\
                                                                                                                                                                                                                                                                             [@b114-molce-39-9-645]

  LH→VTA                   Pharmacology                                                              Intra-VTA orexin induces reinstatement of morphine                                                                               Orexinergic transmission               [@b47-molce-39-9-645]

  VTA→Hipp                 Pharmacology                                                              D1/D2 antagonist blocks acquisition of morphine induced CPP                                                                      Dopaminergic transmission              [@b31-molce-39-9-645]

  VTA→dST                  Pharmacology                                                              MOR antagonist injection in the VTA blocked Fos induction in the dST                                                             Dopaminergic transmission              [@b8-molce-39-9-645]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VTA, ventral tegmental area; NAc, nucleus accumbens; Hipp, hippocampus; BNST, bed nucleus of the stria terminalis; Amy, amygdala; dST, dorsal striatum; RMTg, rostromedial tegmental nucleus; LH, lateral hypothalamus, mPFC, medial prefrontal cortex. CPP, conditioned place preference; CeA, central nucleus of the amygdala; BLA, basolateral amygdala; NMDA, N-methyl-D-aspartate receptor; CaMKII, Ca2+/calmodulin-dependent protein kinase II; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. CB1, cannabinoid receptor type 1
